META-MUST consists of two separate clinical trials, POINT and MERIT. The purpose of the POINT study is to evaluate the relative efficacy of three commonly utilized regional corticosteroids for the initial regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal triamcinolone acetonide; intravitreal dexamethasone implant. The MERIT Trial was designed to find out which intravitreal therapy offers the best balance of effectiveness and tolerability in treating persistent uveitic macular edema in eyes with controlled uveitis but persistent macular edema, specifically by comparing the relative efficacy and safety of intravitreal ranibizumab (Lucentis®) and intravitreal methotrexate to intravitreal dexamethasone implant (Ozurdex®) for the treatment of persistent uveitic macular edema.
|Effective start/end date||9/30/14 → 1/31/22|
- Johns Hopkins University (Sub#2002749092 // 5U10EY024527-03)
- National Eye Institute (Sub#2002749092 // 5U10EY024527-03)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.